By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Predictive Biosciences today said it has completed a Series C financing round, raising $25 million.

Proceeds will be used to complete multi-center clinical trials for Predictive's CertNDx bladder cancer assay and to launch the test through the company's CLIA laboratories, it said in a statement.

CertNDx uses Predictive's Multi-Analyte Diagnostic Readout, or MADR, approach, which combines DNA and protein biomarkers into one assay.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The New York Times' George Johnson muses on cancer's roots in multicellularity.

The San Diego Union Tribune wonders whether Medicare is ready for personalized medicine.

Jun Wang, the chief executive of BGI, has stepped down.

In PNAS this week: human T cell editing with CRISPR, retrotransposons acting as insulators, and more.